vs
Side-by-side financial comparison of Avidia Bancorp, Inc. (AVBC) and Sanara MedTech Inc. (SMTI). Click either name above to swap in a different company.
Sanara MedTech Inc. is the larger business by last-quarter revenue ($27.5M vs $26.8M, roughly 1.0× Avidia Bancorp, Inc.). Avidia Bancorp, Inc. runs the higher net margin — 22.9% vs -5.9%, a 28.8% gap on every dollar of revenue. Avidia Bancorp, Inc. produced more free cash flow last quarter ($24.1M vs $3.9M).
Avidia Bank is an American mutual community bank headquartered in Hudson, Massachusetts. It was founded in 2007 when it was formed by a merger between Hudson Savings Bank and Westborough Bank.
Sanara MedTech Inc. is a US-based medical technology company that develops, manufactures, and distributes innovative surgical, wound care, and post-acute rehabilitation products. It mainly serves healthcare providers, hospitals, and long-term care facilities across North America, with a portfolio of FDA-cleared solutions designed to improve patient outcomes and lower clinical care operational costs.
AVBC vs SMTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.8M | $27.5M |
| Net Profit | $5.3M | $-1.6M |
| Gross Margin | — | 93.2% |
| Operating Margin | 33.3% | 23.5% |
| Net Margin | 22.9% | -5.9% |
| Revenue YoY | — | 4.6% |
| Net Profit YoY | — | 5.3% |
| EPS (diluted) | — | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.8M | $27.5M | ||
| Q3 25 | $28.0M | $26.3M | ||
| Q2 25 | $25.9M | $25.8M | ||
| Q1 25 | $22.9M | $23.4M | ||
| Q4 24 | — | $26.3M | ||
| Q3 24 | — | $21.7M | ||
| Q2 24 | — | $20.2M | ||
| Q1 24 | — | $18.5M |
| Q4 25 | $5.3M | $-1.6M | ||
| Q3 25 | $-907.0K | $-30.4M | ||
| Q2 25 | $3.9M | $-2.0M | ||
| Q1 25 | $-11.6M | $-3.5M | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | — | $-2.9M | ||
| Q2 24 | — | $-3.5M | ||
| Q1 24 | — | $-1.8M |
| Q4 25 | — | 93.2% | ||
| Q3 25 | — | 92.9% | ||
| Q2 25 | — | 92.5% | ||
| Q1 25 | — | 92.2% | ||
| Q4 24 | — | 91.4% | ||
| Q3 24 | — | 90.8% | ||
| Q2 24 | — | 90.0% | ||
| Q1 24 | — | 89.8% |
| Q4 25 | 33.3% | 23.5% | ||
| Q3 25 | -7.0% | 11.2% | ||
| Q2 25 | 19.4% | -0.1% | ||
| Q1 25 | -72.0% | -8.9% | ||
| Q4 24 | — | 18.6% | ||
| Q3 24 | — | 3.6% | ||
| Q2 24 | — | -14.3% | ||
| Q1 24 | — | -8.3% |
| Q4 25 | 22.9% | -5.9% | ||
| Q3 25 | -3.2% | -115.5% | ||
| Q2 25 | 15.0% | -7.8% | ||
| Q1 25 | -50.5% | -15.1% | ||
| Q4 24 | — | -6.5% | ||
| Q3 24 | — | -13.2% | ||
| Q2 24 | — | -17.4% | ||
| Q1 24 | — | -9.5% |
| Q4 25 | — | $-0.32 | ||
| Q3 25 | $-0.05 | $-3.40 | ||
| Q2 25 | — | $-0.23 | ||
| Q1 25 | — | $-0.41 | ||
| Q4 24 | — | $-0.18 | ||
| Q3 24 | — | $-0.34 | ||
| Q2 24 | — | $-0.41 | ||
| Q1 24 | — | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $275.0M | $16.6M |
| Total DebtLower is stronger | — | $46.0M |
| Stockholders' EquityBook value | $379.0M | $5.9M |
| Total Assets | $2.8B | $72.9M |
| Debt / EquityLower = less leverage | — | 7.74× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $275.0M | $16.6M | ||
| Q3 25 | $208.3M | $14.9M | ||
| Q2 25 | $592.5M | $17.0M | ||
| Q1 25 | — | $20.7M | ||
| Q4 24 | — | $15.9M | ||
| Q3 24 | — | $16.3M | ||
| Q2 24 | — | $6.2M | ||
| Q1 24 | — | $2.8M |
| Q4 25 | — | $46.0M | ||
| Q3 25 | — | $45.1M | ||
| Q2 25 | — | $44.2M | ||
| Q1 25 | — | $43.4M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $14.4M | ||
| Q1 24 | — | $9.7M |
| Q4 25 | $379.0M | $5.9M | ||
| Q3 25 | $372.0M | $6.1M | ||
| Q2 25 | $191.4M | $35.4M | ||
| Q1 25 | $186.1M | $36.7M | ||
| Q4 24 | — | $39.4M | ||
| Q3 24 | — | $39.8M | ||
| Q2 24 | — | $41.7M | ||
| Q1 24 | — | $43.3M |
| Q4 25 | $2.8B | $72.9M | ||
| Q3 25 | $2.8B | $71.1M | ||
| Q2 25 | $3.0B | $98.8M | ||
| Q1 25 | $2.7B | $96.4M | ||
| Q4 24 | — | $88.1M | ||
| Q3 24 | — | $88.5M | ||
| Q2 24 | — | $73.4M | ||
| Q1 24 | — | $70.9M |
| Q4 25 | — | 7.74× | ||
| Q3 25 | — | 7.33× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.18× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.4M | $3.9M |
| Free Cash FlowOCF − Capex | $24.1M | $3.9M |
| FCF MarginFCF / Revenue | 89.9% | 14.0% |
| Capex IntensityCapex / Revenue | 16.0% | 0.3% |
| Cash ConversionOCF / Net Profit | 5.32× | — |
| TTM Free Cash FlowTrailing 4 quarters | $40.2M | $2.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.4M | $3.9M | ||
| Q3 25 | $24.1M | $2.2M | ||
| Q2 25 | $-2.3M | $2.7M | ||
| Q1 25 | $-2.2M | $-2.0M | ||
| Q4 24 | — | $932.0K | ||
| Q3 24 | — | $2.1M | ||
| Q2 24 | — | $-1.4M | ||
| Q1 24 | — | $-1.6M |
| Q4 25 | $24.1M | $3.9M | ||
| Q3 25 | $23.3M | $1.1M | ||
| Q2 25 | $-3.3M | $902.7K | ||
| Q1 25 | $-3.9M | $-3.7M | ||
| Q4 24 | — | $859.9K | ||
| Q3 24 | — | $2.0M | ||
| Q2 24 | — | $-1.5M | ||
| Q1 24 | — | $-1.7M |
| Q4 25 | 89.9% | 14.0% | ||
| Q3 25 | 83.2% | 4.2% | ||
| Q2 25 | -12.8% | 3.5% | ||
| Q1 25 | -16.9% | -15.9% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | — | 9.4% | ||
| Q2 24 | — | -7.3% | ||
| Q1 24 | — | -9.0% |
| Q4 25 | 16.0% | 0.3% | ||
| Q3 25 | 3.1% | 4.0% | ||
| Q2 25 | 3.7% | 6.8% | ||
| Q1 25 | 7.2% | 7.4% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 0.4% |
| Q4 25 | 5.32× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.60× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVBC
Segment breakdown not available.
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
